CareDx (CDNA) Q1 2026: Testing Services Revenue Jumps 48% as Portfolio Reshapes for $12B TAM
CareDx delivered a transformative quarter, accelerating core testing services growth while executing two major portfolio moves: the divestiture of its lab products business and the acquisition of Naveris, a leader in viral-mediated oncology diagnostics. Management raised guidance, underscoring confidence in expanded precision medicine ambitions and operational leverage from workflow integration and digital solutions. Investors should watch for further evidence of scale and margin capture as CareDx pivots to a more focused, high-growth model.
Summary
- Testing Services Outperformance: Core testing and digital solutions growth outpaced legacy segments following a major portfolio reshuffle.
- Strategic Oncology Expansion: Naveris acquisition positions CareDx to capture a differentiated share of the $4.5B viral-driven cancer market.
- Margin Leverage Focus: Workflow automation and digital integration drive operational efficiency and higher per-test returns.
Performance Analysis
CareDx’s Q1 2026 results reflect a decisive shift toward high-value, scalable diagnostics, with testing services revenue up 48% and digital solutions up 33%, now comprising the overwhelming majority of the business mix. Testing volumes climbed 17% to nearly 55,000, and non-GAAP gross margin reached 73%, signaling strong operational control. Core testing services, which now represent the foundation of CareDx’s revenue model, benefited from increased adoption, improved claims management, and enhanced workflow integration with transplant centers.
The company’s decision to divest its lab products business, which posted a 4% YoY revenue decline, clarifies strategic focus and delivers $170 million in upfront cash. This move, combined with robust cash collections and positive operating cash flow, provides financial flexibility for growth investments. Adjusted EBITDA surged over 300% YoY, reflecting not just revenue growth but also disciplined expense management and improving scale in the core business lines.
- Testing Services Mix Shift: Core testing and digital now drive 90%+ of pro forma revenue, reducing exposure to lower-growth product lines.
- Revenue Cycle Improvements: Out-of-period collections and higher accrual rates contributed to a rising revenue per test, with further upside as workflow integrations mature.
- Cash and Capital Strength: $198 million in cash, no debt, and a $100 million share repurchase authorization underscore balance sheet resilience.
With guidance raised for both revenue and EBITDA, CareDx is signaling confidence in its ability to sustain double-digit growth while expanding margins, even before factoring in upside from the Naveris acquisition.
Executive Commentary
"At CareDx, our growth strategy is focused on extending our leadership in precision medicine testing services and patient and digital solutions by addressing markets where our core competencies give us the right to win... Our organic growth strategy is anchored on three connected drivers. First is our pipeline programs. Innovation is central to how we maintain leadership and extend our model into new markets and grow our TAM."
John Hanna, President and CEO
"Total revenue increased 39% to 118 million... Our non-GAAP gross margins increased to 73%... Cash collections increased 52% to $121 million. Cash flow from operations were $4 million this quarter and $72 million over the last four quarters. And we ended the quarter with $198 million in cash and cash equivalents and no debt."
Keith Kennedy, COO and CFO
Strategic Positioning
1. Precision Medicine Focus
CareDx is doubling down on its core strength: precision diagnostics for transplant and specialty oncology. By divesting the lab products business and acquiring Naveris, CareDx is concentrating resources on high-value, repeat testing markets with entrenched provider relationships and strong reimbursement frameworks. The company estimates its total addressable market (TAM) now exceeds $12 billion, spanning solid organ transplant and viral-mediated oncology.
2. Workflow and Digital Integration
Workflow automation is emerging as a competitive moat, with 70% of U.S. transplant centers using at least one CareDx digital solution. The company’s push to embed its platform into Epic and other clinical systems is driving more consistent ordering, reporting, and cash collection. Management targets 50% of testing volume running through Epic-integrated sites by year-end, supporting both operational efficiency and higher test adherence rates.
3. Oncology Platform Expansion
The Naveris acquisition brings a validated, Medicare-covered MRD (minimal residual disease) platform for HPV-driven cancers, with 130,000 commercial tests performed and 2,000 active ordering physicians. The test is reimbursed at $1,800 per assay and is already covered for 100 million lives. Naveris’ technology, based on tumor tissue modified viral DNA (TTMV), differentiates CareDx in a specialty oncology segment with high barriers to entry and growing incidence rates.
4. Evidence Generation and Clinical Advocacy
CareDx’s evidence-first approach continues to pay dividends, with more than 50 abstracts and 16 oral presentations at ISHLT, and ongoing studies (e.g., Acrobat, MAPLE, MERIT) supporting new indications. This scientific leadership underpins payor confidence, provider adoption, and the company’s ability to expand testing into new disease states.
5. Capital Allocation Discipline
With the lab products divestiture and new share repurchase authorization, management is demonstrating capital discipline, prioritizing investments that directly support the core business and high-return innovation opportunities.
Key Considerations
Q1 2026 marks a turning point for CareDx, as management executes a portfolio realignment and accelerates its precision medicine strategy. The quarter’s results and commentary highlight several strategic factors for investors:
Key Considerations:
- Oncology Channel Leverage: Naveris’ established provider relationships and reimbursement unlock a near-term $1.5B MRD opportunity without the need to build new sales infrastructure.
- Margin Expansion Potential: Automation, scale, and digital integration are expected to yield further cost-per-test reductions and improved revenue cycle management, with management targeting a third reduction in Naveris’ cost structure.
- Transplant Market Runway: Despite flat underlying procedure volumes, surveillance and for-cause testing adoption remain in early innings, with kidney and lung showing substantial growth potential.
- Evidence and Advocacy Moat: The company’s deep clinical trial pipeline and real-world data support durable adoption and payor alignment, especially as molecular testing becomes standard of care.
Risks
CareDx faces several execution and market risks: Integration of Naveris will require operational focus, especially as workflow automation and scale are critical to margin targets. Reimbursement dynamics, including potential LCD changes for transplant testing and annual ADLT resets for Naveris, could introduce volatility. Competitive threats in molecular diagnostics remain, though management asserts a differentiated technology and evidence base. Macro trends in transplant procedure volumes and oncology testing adoption must be closely monitored, as growth is partly decoupled from underlying procedure rates.
Forward Outlook
For Q2 2026, CareDx guided to:
- Sequential testing volume increase of approximately 1,700 tests
- Revenue per test expected to rise, with further out-of-period revenue collections in Q2 and Q3
For full-year 2026, management raised guidance:
- Revenue of $447 to $465 million (20% YoY growth at midpoint)
- Adjusted EBITDA of $43 to $57 million (58% YoY growth at midpoint)
Management highlighted continued investment in workflow automation, digital integration, and clinical pipeline expansion as key levers for the remainder of the year. The Naveris acquisition is not yet included in revenue guidance, providing potential upside if integration accelerates.
- Lab products divestiture expected to close by end of Q3, with pro forma core business growth of 23% YoY
- Gross margins modeled in the 68% to 71% range, with operating expenses stable as a percentage of revenue
Takeaways
CareDx exits Q1 2026 as a more focused, higher-growth diagnostics company, with strategic moves that position it to capitalize on large specialty markets in both transplant and oncology.
- Core Testing and Digital Drive Growth: Portfolio simplification and workflow integration are accelerating revenue and margin expansion in the core business.
- Naveris Adds Oncology Upside: The acquisition brings a differentiated, high-growth MRD platform with near-term revenue and long-term pipeline potential.
- Execution Remains Critical: Investors should monitor Naveris integration, margin capture from automation, and ongoing reimbursement developments for both transplant and oncology testing.
Conclusion
CareDx’s Q1 2026 results and strategic actions signal a clear pivot to scalable, high-margin diagnostics, with the Naveris acquisition and lab products divestiture sharpening focus on $12B+ in precision medicine TAM. Execution on workflow integration, evidence generation, and operational leverage will be decisive for sustaining growth and margin expansion in coming quarters.
Industry Read-Through
CareDx’s portfolio moves and operational focus highlight a broader trend in diagnostics: companies are concentrating on high-value, repeat testing markets with strong reimbursement and workflow integration as a differentiator. The Naveris deal signals increasing competition for MRD platforms in oncology, especially those with established payor coverage and digital-enabled adoption. Lab products divestitures and digital workflow investments may accelerate across the sector as diagnostics peers seek scale, margin, and clinical relevance. Investors should watch for further consolidation and digital integration moves among precision medicine and specialty lab players.